Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing
ISTANBUL--(BUSINESS WIRE)--#MSKCC--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Ke...